One year clinical outcomes in patients with insulin-treated diabetes mellitus and non-insulin-treated diabetes mellitus compared to non-diabetics after deployment of the bio-engineered COMBO stent

详细信息    查看全文

• 作者：Deborah N. Kalkman^a ; ¹ ; ^{d.n.kalkman@amc.uva.nl} ; Pier Woudstra^a ; ¹ ; ^{p.woudstra@amc.uva.nl} ; Peter den Heijer^b ; ¹ ; ^{pdheyer@amphia.nl} ; Ian B.A. Menown^c ; ¹ ; ^{ian.menown@southerntrust.hscni.net} ; Andrejs Erglis^d ; ¹ ; ^{a.a.erglis@stradini.lv} ; Harry Suryapranata^e ; ¹ ; ^{h.suryapranata@cardio.umcn.nl} ; Karin E. Arkenbout^f ; ¹ ; ^{e.arkenbout@amc.uva.nl} ; André ; s Iñ ; iguez^g ; ¹ ; ^{andres.iniguez.romo@sergas.es} ; Arnoud W.J. van &rsquo ; t Hof^h ; ¹ ; ^{a.w.j.vant.hof@isala.nl} ; Philippe Mullerⁱ ; ¹ ; ^{philmul57@gmail.com} ; Jan G. Tijssen^j ; ¹ ; ^{tijssenj@outlook.com} ; Robbert J. de Winter^j ; ¹ ; ^{r.j.dewinter@amc.uva.nl}
• 关键词：Endothelial progenitor cell ; Diabetes mellitus ; Drug-eluting stent ; Percutaneous coronary intervention ; Clinical outcomes
• 刊名：International Journal of Cardiology
• 出版年：2017
• 出版时间：1 January 2017
• 年：2017
• 卷：226
• 期：Complete
• 页码：60-64
• 全文大小：351 K
• 卷排序：226

文摘

The COMBO stent is a novel sirolimus-eluting stent with a luminal anti-CD34 + antibody layer to promote vessel healing. No data is currently available on clinical outcomes after treatment with this novel bio-engineered device in diabetic patients. We evaluate clinical outcomes at twelve months after COMBO stent placement in patients without diabetes mellitus (non-DM), patients with non-insulin-treated diabetes mellitus (nITDM) and patients with insulin-treated diabetes mellitus (ITDM).MethodsThis study is a pre-specified subgroup analysis of the 1000 patient all-comers REMEDEE Registry. The primary endpoint is target lesion failure (TLF), which is a combined endpoint consisting of cardiac death, target vessel-myocardial infarction (tv-MI) and target lesion revascularization (TLR) at twelve months follow-up. Kaplan Meier method is used with log rank to compare outcomes between groups.ResultsThis subgroup analysis includes 807 non-DM, 117 nITDM and 67 ITDM. Kaplan–Meier estimates for TLF at twelve months are 4.4% in non-DM, 6.8% in nITDM and 20.3% in ITDM, p < 0.001 (non-DM vs nITDM p = 0.244, non-DM vs ITDM p < 0.001).ConclusionsThis study gives the first insight into the impact of insulin-treated diabetes mellitus on clinical outcome of patients treated with the novel COMBO stent. At one year after COMBO stent placement significantly higher rates of target lesion failure are seen in patients with ITDM compared to patients with nITDM and patients without DM.